No Benefit Seen With Adjuvant Nivolumab in Gastric/GEJ Cancer

Adding nivolumab to adjuvant chemotherapy did not improve relapse-free survival in a phase 3 trial of patients with gastric/GEJ cancer.

Related Keywords

Japan ,Shizuoka ,Nagaizumi ,China ,Taiwan ,Masanori Terashima ,Shizuoka Cancer Center , ,